Related Experiment Video
Updated: Feb 17, 2026

05:58
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
3.9K
Estimation of immune cell content in tumour tissue using single-cell RNA-seq data
Max Schelker1,2, Sonia Feau1, Jinyan Du1
1Merrimack Pharmaceuticals, Inc., Cambridge, MA, 02139, USA.
Nature Communications
|December 13, 2017
Summary
Understanding a solid tumour's immune cell composition is key for predicting immunotherapy response. This study shows tumour-derived gene expression profiles are essential for accurate cell type deconvolution from bulk data.
Area of Science:
- Immunology
- Bioinformatics
- Computational Biology
Background:
- Immune cell infiltration in solid tumours influences patient response to immunotherapy.
- Accurate characterization of tumour microenvironment cellular composition is crucial for personalized cancer treatment.
Purpose of the Study:
- To develop and validate a mathematical deconvolution method for determining solid tumour cellular composition from bulk gene expression data.
- To assess the necessity of tumour-derived reference gene expression profiles (RGEPs) for accurate deconvolution.
Main Methods:
- Mathematical deconvolution of bulk gene expression data.
- Utilizing indication-specific and cell type-specific RGEPs derived from single-cell RNA sequencing of tumour tissues.
- Comparison of tumour-derived RGEPs versus peripheral blood-derived RGEPs.
Main Results:
- Tumour-derived RGEPs are essential for accurate deconvolution; peripheral blood RGEPs are insufficient.
- Successfully distinguished nine major cell types and three T cell subtypes within solid tumours.
- Enabled estimation of various immune and stromal cell types, their ratios, and improved malignant cell gene expression profiles.
Conclusions:
- Accurate deconvolution of tumour immune cell composition requires tumour-specific reference gene expression profiles.
- This method enhances understanding of the tumour microenvironment and aids in predicting immunotherapy response.

